Unlocking Hope: Ovarian Cancer Pipeline Innovations and Breakthrough Therapy

DelveInsight’s 2025 report on the Ovarian Cancer Pipeline delivers in-depth analysis of over 180 companies and more than 200 drugs in development. It features profiles of pipeline therapies across clinical and non-clinical stages, assessments by product category, development phase, delivery route, and molecular type. The report also discusses inactive projects in this therapeutic area.

Eager to learn about the newest advancements in the Ovarian Cancer Pipeline? Discover the treatments and studies capturing attention in the Ovarian Cancer Pipeline Outlook Report

Key Highlights from the Ovarian Cancer Pipeline Report

• On October 3, 2025, AGO Research GmbH unveiled a study designed to assess safety and feasibility in a phased manner. A trial steering committee will convene between cohorts to evaluate progress before advancing to the next phase. Safety monitoring for the initial cohort will span 90 days from the first treatment dose.

• On October 3, 2025, Daiichi Sankyo initiated a clinical trial to compare the effectiveness and safety of T-DXd combined with bevacizumab against bevacizumab alone as initial maintenance therapy for patients with HER2-expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

• DelveInsight’s Ovarian Cancer Pipeline analysis showcases a thriving sector with over 180 active organizations creating more than 200 therapies for Ovarian Cancer management.

• Leading companies in Ovarian Cancer include Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others.

• Promising therapies include SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and more.

Want to see which firms are spearheading progress in Ovarian Cancer? Explore the full pipeline details in the Ovarian Cancer Clinical Trials Assessment

The Ovarian Cancer Pipeline Report offers a comprehensive overview of the disease, the current pipeline landscape, and evaluations of major therapies. It also identifies unmet needs in Ovarian Cancer care.

Understanding Ovarian Cancer

Ovarian cancer ranks as the top cause of mortality among gynecological cancers in women and is the fifth leading cause of female deaths overall. Most diagnoses occur at advanced stages, resulting in poor prognosis. Current screening methods lack strong predictive power, exacerbating the issue. Comprehensive gynecological exams, transvaginal ultrasounds, and markers like CA-125 are used for early detection but have not significantly reduced morbidity or mortality.

Profiles of Emerging Ovarian Cancer Drugs

• Atezolizumab: Genentech
  Atezolizumab is a humanized IgG1 monoclonal antibody with two heavy chains (448 amino acids each) and two light chains (214 amino acids each), produced in Chinese hamster cells. It was modified to remove Fc-effector functions through a single amino acid change (asparagine to alanine at position 298), creating a non-glycosylated antibody with minimal Fc receptor binding, thus avoiding depletion of PD-L1-expressing cells. It blocks PD-L1 from interacting with PD-1 and B7.1 receptors, preventing inhibitory signals to T cells. The therapy is in Phase III trials for Ovarian Cancer.

• Tisotumab Vedotin: Genmab
  Tisotumab Vedotin, also referred to as HuMax-TF, HuMax®-TF-ADC, or TF-011-MMAE, is an antibody-drug conjugate targeting tissue factor (TF), a protein linked to tumor signaling and blood vessel formation. It pairs an anti-TF antibody with monomethyl auristatin E (MMAE) via a cleavable linker. The drug is in Phase II trials for Ovarian Cancer.

• SON-1010: Sonnet Biotherapeutics
  SON-1010 is a proprietary form of human IL-12, engineered with Sonnet's fully human albumin-binding (FHAB®) technology to focus on the tumor microenvironment and prolong the drug's presence and effects. Sonnet and Roche have a collaboration agreement to investigate SON-1010 combined with atezolizumab in platinum-resistant ovarian cancer patients. It is currently in Phase I/II development for Ovarian Cancer.

• DS-6000a: Daiichi Sankyo Company
  DS-6000a is an antibody-drug conjugate featuring a humanized anti-CDH6 IgG1 antibody linked to a topoisomerase I inhibitor payload. It binds specifically to CDH6 on tumor surfaces, gets internalized, and releases the payload to cause cell death. Preclinical studies showed tumor growth inhibition and regression in CDH6-positive renal cell carcinoma and ovarian cancer models. The drug is in Phase I trials for Ovarian Cancer.

If you're monitoring active Ovarian Cancer Clinical Trials, this summary is crucial. Learn about the innovations in Ovarian Cancer Treatment Drugs

The Ovarian Cancer Pipeline report provides insights into:

• Detailed profiles of companies advancing Ovarian Cancer therapies, including the total treatments per company.

• Segmentation of therapeutic candidates into early, mid, and late development stages for Ovarian Cancer treatment.

• Companies focused on targeted drug development, covering active and inactive (dormant or halted) initiatives.

• Drugs in progress, evaluated by development stage, administration route, target receptor, monotherapy or combination, mechanism of action, and molecular type.

• Thorough analysis of partnerships (including company-to-company and company-academia), licensing agreements, and funding to drive Ovarian Cancer market growth.

Ovarian Cancer Companies

Key players include Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others.

Ovarian Cancer Therapeutic Assessment by Route of Administration

The report categorizes pipeline drugs by delivery methods, such as:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Ovarian Cancer Products by Molecule Type

Products are classified by molecular structures, including:

• Recombinant fusion proteins

• Small molecules

• Monoclonal antibodies

• Peptides

• Polymers

• Gene therapies

From promising new candidates to market intelligence, the Ovarian Cancer Pipeline Report covers it all—explore at Ovarian Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Ovarian Cancer Pipeline Report

• Coverage: Worldwide.

• Ovarian Cancer Companies: Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others.

• Ovarian Cancer Therapies: SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.

• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, or Both.

• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Stay updated in healthcare research—uncover upcoming developments in the Ovarian Cancer Treatment landscape through this detailed review at Ovarian Cancer Emerging Drugs and Major Players

Table of Contents

1. Introduction

2. Executive Summary

3. Ovarian Cancer: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Ovarian Cancer- DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Atezolizumab: Genentech

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. Tisotumab Vedotin: Genmab

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I)

14. DS-6000a: Daiichi Sankyo Company

15. Drug profiles in the detailed report.....

16. Preclinical and Discovery Stage Products

17. Product Name: Company Name

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Ovarian Cancer Key Companies

21. Ovarian Cancer Key Products

22. Ovarian Cancer- Unmet Needs

23. Ovarian Cancer- Market Drivers and Barriers

24. Ovarian Cancer- Future Perspectives and Conclusion

25. Ovarian Cancer Analyst Views

26. Ovarian Cancer Key Companies

27. Appendix

About DelveInsight

DelveInsight is a premier market research and consulting firm specializing in healthcare, offering high-quality intelligence and analysis to inform strategic decisions. Our expert team, with extensive knowledge of life sciences and healthcare, provides customized solutions and global insights. Contact us for accurate, timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com